RxDoctor Payments Data

Jorge Lacen, MD

General Practice · Caguas, PRNPI 1023422425

Payments from drug & device makers

$1,226in general payments, 2019–2025

Across 18 payments — averaging $68.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$267
  • AbbVie$181
  • Bayer$132
  • Axsome Therapeutics, Inc.$122
  • AstraZeneca$97
  • Lilly USA, LLC$97
  • plus $329 from 5 others

What the payments were for

  • Food & beverage$1,226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,226 in reported general payments places this provider in the 85th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$62,120
Medicare patients
256
Services billed
1,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$96,253
OzempicSemaglutide49$67,904
MounjaroTirzepatide39$47,354
JardianceEmpagliflozin27$30,793
TrulicityDulaglutide11$20,234
XareltoRivaroxaban11$16,525
EntrestoSacubitril/Valsartan11$12,951
Aripiprazole17$8,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,592
SymbicortBudesonide/Formoterol Fumarate24$5,818
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,744
Testosterone21$4,794
Atorvastatin Calcium344$3,442
Albuterol Sulfate HfaAlbuterol Sulfate107$2,734
Pregabalin40$2,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$96,25382 claims
Novo NordiskOzempic$19$67,90449 claims
Lilly USA, LLCMounjaro, Trulicity$97$67,58750 claims
GSKTrelegy Ellipta$267$7,59212 claims
AstraZenecaSymbicort$97$5,81824 claims
AbbVieSynthroid$181$1,27913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →